Observational studyHealth and quality of life outcomes2025
Non-motor symptoms as critical predictors of quality of life in Parkinson's disease: a machine learning approach.
Observational study in Health and quality of life outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) considerably impacts health-related quality of life (HRQoL) through motor and non-motor symptoms. The Parkinson's Disease Questionnaire-39 (PDQ-39) is the most widely used tool to assess HRQoL, encompassing eight dimensions and a Summary Index providing an overall score. Despite advances in machine learning (ML) for predicting disease symptoms and progression, its application to predict HRQoL across these dimensions remains underexplored.
methodsThis study uses complete-case data for 478 of 861 patients from PRISM, a cross-sectional observational survey conducted in six European countries in 2018-2019. Participants were adults with PD recruited through advocacy groups and clinical centers who completed online assessments, providing data on demographics, medication, comorbidities, and disease characteristics (Tolosa et al., 2021). ML models were trained to predict PDQ-39 dimensions and Summary Index scores (0-100; higher = worse HRQoL). Features were preselected using the Boruta algorithm on the training data. Model selection was based on the lowest mean RMSE from 100 bootstrap resamples on the training set. Selected models were then retrained using 1000 bootstrap resamples for robust performance estimation. Final performance was evaluated on a held-out 20% validation set using R², MAE, and RMSE. Feature importance was assessed using permutation importance with MAE loss (100 permutations) on the held-out validation set. Factor Analysis of Mixed Data (FAMD) was used to explore patterns between non-motor symptoms and PDQ-39.
resultsSelected models: xgbTree (Summary Index; Activities of Daily Living) and gaussprPoly (all other PDQ-39 dimensions). On the validation set, Summary Index/ Cognitions showed the strongest performance with R² = 0.56/0.53, MAE = 9.60/12.39, RMSE = 12.66/16.20. Permutation feature importance ranked the Non-Motor Symptoms Questionnaire score (sum of 30 non-motor symptoms, range 0-30) as the most important predictor across all models. FAMD showed clustering of Social Support, Bodily Discomfort, and Stigma dimensions with Anxiety.
conclusionsOur findings demonstrate the critical role of non-motor symptoms in predicting HRQoL in patients with PD. While ML models effectively predict overall HRQoL and cognitive aspects, achieving comparable performance on other dimensions may require additional variables to reduce error. These insights emphasize comprehensive treatment strategies addressing both motor and non-motor symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.